Twist Bioscience Corporation TWST Liabilities Related to Investment Contracts, Fair Value Disclosure

Other financials

Revenue$110.7M+19.3%

Gross profit$57.1M+24.1%

Operating income-$45.9M-10.4%

Net income-$44.0M-11.9%

EPS (diluted)-$0.71-7.6%

Cash & equivalents$124.9M-41.4%

Total debt$110.8M+16.3%

Total equity$455.1M+3.4%

Total assets$676.2M+13.5%

Operating cash flow-$17.6M-35.2%

CapEx$7.9M+90.3%

Free cash flow-$25.4M-48.5%

Market cap$5.45B+24.4%

Enterprise value$5.44B+30.4%

P/S13.3×+0.7×

Gross margin52.1%+5.4pp

Operating margin-33.9%-9.9pp

Net margin-19.8%-7.7pp

FCF margin-23.2%+7.0pp

Return on equity-18.2%-6.3pp

Debt / equity0.2×0.0×

Current ratio2.7×-1.8×

Reported directly by Twist Bioscience Corporation in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure.

The official record: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Twist Bioscience Corporation's liabilities related to investment contracts, fair value disclosure?: Twist Bioscience Corporation (TWST) reported liabilities related to investment contracts, fair value disclosure of $5M in Q1 2026.